Close
Achema middle east
swop processing & packaging

ReciBioPharm secures a significant grant to advance RNA manufacturing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

CPHI 2025: BENEO to present galenIQâ„¢ as the granulation binder of choice

At this year’s CPHI Europe in Frankfurt (28–30 October),...
  • 3-year grant received from the Bill & Melinda Gates Foundation to enhance RNA production technologies
  • Grant enables global implementation of the RNA Continuous Manufacturing platform and advancement of
  • Process Analytical Technologies (PAT), developed through an MIT project funded by the FDA
  • Focused on improving access to RNA therapeutics in Low- and Middle-Income Countries (LMICs)

ReciBioPharm, a division of Recipharm and a leading Contract Development and Manufacturing Organisation (CDMO), has been awarded a three-year grant from the Bill & Melinda Gates Foundation (Gates Foundation). The funding will support the global deployment of xRNA Continuous Manufacturing technologies to LMICs with a strong focus on the development of state-of-the-art inline PAT capabilities and predictive analytics software. ReciBioPharm’s platform will improve the scalability, quality, and accessibility of RNA-based medicines and will help advance its goal of developing fully integrated, continuous processes across the biomanufacturing industry.

Vikas Gupta, President of ReciBioPharm, said: “This grant represents a significant milestone in our commitment to advancing RNA manufacturing technologies that meet FDA standards. We are proud to lead this transformative effort, expanding access to RNA-based solutions for underserved regions.â€

“Our previously-announced collaboration with MIT has underscored the potential of continuous manufacturing for RNA therapeutics,†added Aaron Cowley, Chief Scientific Officer of ReciBioPharm. “This grant will help to strengthen our role as a pioneer in innovation and support our mission to make lifesaving technologies more accessible.â€

This project exemplifies ReciBioPharm’s dedication to addressing global health challenges by combining advanced technologies, scalable processes, and GMP standards to deliver critical RNA-based solutions worldwide.

ReciBioPharm
Company Logo

Latest stories

Related stories

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

CPHI 2025: BENEO to present galenIQâ„¢ as the granulation binder of choice

At this year’s CPHI Europe in Frankfurt (28–30 October),...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »